ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Daniel Gaudet(Brigham and Women's Hospital), G. Kees Hovingh(Novo Nordisk (Denmark)), Jesper Gromada(Rapt Therapeutics (United States)), Marina Cuchel(University of Pennsylvania), Robert Pordy(Inserm), Diane Brisson(Université de Montréal), Poulabi Banerjee(Cardiovascular Institute of the South), Viktoria Gusarova(Regeneron (United States)), Neil Stahl(Arthritis and Rheumatism Associates), George D. Yancopoulos(Regeneron (United States)), Étienne Khoury(Université de Montréal), Zahid Ahmad(The University of Texas Southwestern Medical Center), Kuo‐Chen Chan(Regeneron (United States)), William J. Sasiela(Inserm), Daniel A. Gipe(Regeneron (United States)), Kuang-Yuh Chyu, Prediman K. Shah(Cedars-Sinai Medical Center)
Cited by 329
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
|New England Journal of Medicine|2023|2.6k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k